Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Pregabalin
11 evidence topics · 10 sources
FDA-approved indications of pregabalin in the United States
European Union authorization for generalized anxiety disorder
CANMAT guideline: first-line agent and second-line adjunctive therapy
“The anticonvulsant pregabalin is also a recommended first-line therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pregabalin: The anticonvulsant pregabalin was more effective than placebo in RCTs” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pregabalin was more effective than venlafaxine XR in one RCT” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Second-line adjunctive therapies: Adjunctive pregabalin demonstrated good efficacy in a large RCT in patients with GAD who had an inadequate response to prior treatments (Level 2)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
NICE guideline: pregabalin when SSRIs and SNRIs are not tolerated
BAP guideline: alternative initial treatment, augmentation, and adverse effects
WFSBP guideline: recommended medications and national approval
Network meta-analysis: HAM-A difference from placebo
Meta-analysis of placebo-controlled trials: effect size and dropout
“We included eight randomized-controlled trials (n=2299) in our study, comparing the use of PGB in different dosages and placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In terms of the main outcome, PGB was found to be superior to the placebo group (Hedges' g=0.37; 95% confidence interval 0.30-0.44).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No difference between PGB and placebo groups was observed in terms of the dropout rates.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“PGB was comparable to benzodiazepines in clinical response, but had lower dropout rates than benzodiazepine.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Onset, weight gain, and abuse liability
“Pregabalin is reported to be generally well-tolerated in adult patients with GAD and has a rapid onset of action compared to many other pharmacotherapies, approximately one week, as well as comparable efficacy to benzodiazepines” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most significant treatment limiting adverse event appears to be the weight gain associated with pregabalin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, pharmacovigilance data suggest that both pregabalin (and gabapentin) have abuse liability and are associated with overdose fatalities” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote